Neurology - Others-Synth. (2)
|
Modality |
Indication |
Targets |
Stage |
Company |
Project No. |
Detail |
| 1 |
Phase 1 Clinical Development of Cerium Oxide-Based Nanozyme CX213 for the Treatment of Subarachnoid Hemorrhage as an Orphan Drug |
| Others-Synth. |
SAH |
활성산소(ROS) |
Phase 1 |
Cenyx Biotech Inc. |
RS-2025-02183050 |
|
| 2 |
Non.clinical study completion and manufacturing system development of CX301 for the development of orphan drug on malignant ischemic stroke |
| Others-Synth. |
Cerebral infarction |
ROS.related inflammation |
Preclinical |
Cenyx Biotech Inc. |
RS-2023-00284156 |
|